Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.

Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 371, Suchdauer: 0.73s

12 3 4 5 6 7 8 9 10 11 weiter »

1
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin

von Ugalde, Anna ; Tothill, Richard W. ; Quinn, Stephen ; et al.

BMC Cancer. 25(1)
- Zum Volltext in PubMed Central
Merkliste

2
Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience

von Kashyap, Raghava ; Alipour, Ramin ; Boehm, Emma ; et al.

European Journal of Nuclear Medicine and Molecular Imaging. 52(10):3672-3681
- Zum Volltext (via ReDI)
Merkliste

3
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

von Kwan, Edmond M. ; Ng, Sarah W. S. ; Tolmeijer, Sofie H. ; et al.

Nature Medicine. 31(8):2722-2736
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

4
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

von Kostos, Louise ; Buteau, James P ; Xie, Jing ; et al.

In The Lancet Oncology November 2025 26(11):1479-1488
- View full text via DOI
Merkliste

5
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

von Buteau, James P ; Kostos, Louise ; Jackson, Price A ; et al.

In The Lancet Oncology August 2025 26(8):1009-1017
- View full text via DOI
Merkliste

6
Dose-Response Relationships Between Radiation Exposure, Bone Marrow Function as Measured by 18F-Fluorothymidine Positron Emission Tomography, and Lymphocyte Counts During Chemoradiation for Non-Small Cell Lung Cancer

von MacManus, Michael P. ; Prins, Elizabeth ; Xie, Jing ; et al.

In International Journal of Radiation Oncology, Biology, Physics 1 February 2025 121(2):375-387
- View full text via DOI
Merkliste

7
Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms

von Emma Boehm ; Terry Hung ; Tim Akhurst ; et al.

Endocrine Oncology, Vol 4, Iss 1, Pp 1-12 (2024)

Schlagworte: ectopic cushing’s syndrome; neuroendocrine neoplasms; peptide receptor radionuclide therapy; radionuclide therapy; theranostics; Diseases of the endocrine glands. Clinical endocrinology; RC648-665; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- View full text via DOI
Merkliste

8
Response to COVID-19 vaccination imaged by PD-L1 PET scanning

von MacManus, Michael P ; Akhurst, Tim ; Lewin, Sharon R ; et al.

EJNMMI Reports. 8(1)
- Zum Volltext in PubMed Central
Merkliste

9
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

10
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

von Akhurst, Tim ; Alipour, Ramin ; Bailey, Dale ; et al.

In The Lancet Oncology January 2024 25(1):99-107
- View full text via DOI
Merkliste

11
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study—TROG 18.06

von Barry, Nathaniel ; Francis, Roslyn J. ; Ebert, Martin A. ; et al.

European Journal of Nuclear Medicine and Molecular Imaging. 50(13):3970-3981
- Zum Volltext (via ReDI)
Merkliste

12
Diagnostic performance of positron emission tomography in the staging of pseudomyxoma peritonei

von Flood, Michael P. ; Kong, Joseph C. ; Pham, Toan ; et al.

In European Journal of Surgical Oncology July 2022 48(7):1606-1613
- View full text via DOI
Merkliste

13
Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience

von Narasimhan, Vignesh ; Wilson, Kasmira ; Britto, Maneka ; et al.

In Journal of Gastrointestinal Surgery April 2020 24(4):899-906
- View full text via DOI
Merkliste

14
First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)

von Pham, Toan ; Pereira, Lloyd ; Roth, Sara ; et al.

In Contemporary Clinical Trials Communications December 2019 16
- View full text via DOI
Merkliste

15
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol

von Christian Wichmann ; Sagun Parakh ; Gerard G Hanna ; et al.

BMJ Open, Vol 12, Iss 11 (2022)

Schlagworte: Medicine
- View full text via DOI
Merkliste

16
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

von Thang, Sue Ping ; Violet, John ; Sandhu, Shahneen ; et al.

In European Urology Oncology November 2019 2(6):670-676
- View full text via DOI
Merkliste

17
Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT

von Zidan, Lamiaa ; Iravani, Amir ; Kong, Grace ; et al.

European Journal of Nuclear Medicine and Molecular Imaging. 48(1):204-216
- Zum Volltext (via ReDI)
Merkliste

18
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment

von Iravani, Amir ; Osman, Medhat M. ; Weppler, Alison M. ; et al.

European Journal of Nuclear Medicine and Molecular Imaging. 47(12):2776-2786
- Zum Volltext (via ReDI)
Merkliste

19
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

20
SUVfdg: A standard-uptake-value (SUV) body habitus normalizer specific to fluorodeoxyglucose (FDG) in humans

von Beattie, Bradley J. ; Akhurst, Tim J. ; Augensen, Finn ; et al.

PLOS ONE ; volume 17, issue 4, page e0266704 ; ISSN 1932-6203
- View full text via BASE
Merkliste

21
SUVfdg: A standard-uptake-value (SUV) body habitus normalizer specific to fluorodeoxyglucose (FDG) in humans

von Bradley J. Beattie ; Tim J. Akhurst ; Finn Augensen ; et al.

PLoS ONE, Vol 17, Iss 4 (2022)

Schlagworte: Medicine; Science
- Zum Volltext in DOAJ
Merkliste

22
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

von Ferdinandus, Justin ; Violet, John ; Sandhu, Shahneen ; et al.

European Journal of Nuclear Medicine and Molecular Imaging. 47(10):2322-2327
- Zum Volltext (via ReDI)
Merkliste

23
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

von Hofman, Michael S ; Violet, John ; Hicks, Rodney J ; et al.

In The Lancet Oncology June 2018 19(6):825-833
- View full text via DOI
Merkliste

24
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

25
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

von Buteau, James P ; Martin, Andrew J ; Emmett, Louise ; et al.

The Lancet Oncology ; volume 23, issue 11, page 1389-1397 ; ISSN 1470-2045
- View full text via BASE
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag